EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 April 2012
EMA/222193/2012
Human Medicines Development and Evaluation

Public statement

Livensa (testosterone)

Withdrawal of the marketing authorisation in the European Union

On 28 July 2006 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Livensa (testosterone). Livensa is approved for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopausal) women receiving concomitant estrogen therapy.

The Marketing Authorisation Holder (MAH) responsible for Livensa was Warner Chilcott Deutschland GmbH. The European Commission was notified by letter dated 06 February 2012 of the MAH's decision to voluntarily withdraw the marketing authorisation for Livensa for commercial reasons.

Livensa has not been marketed anywhere in the European Union and there is no intention to market Livensa in the future.

On 15 March 2012 the European Commission issued a decision to withdraw the marketing authorisation for Livensa. Pursuant to this decision the European Public Assessment Report for Livensa will be updated to reflect that the marketing authorisation is no longer valid.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8613
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union